Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.60 |
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | PNMT | P11086 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447950 | 1.00 | TAAR1 (0.60) | TAAR1IDO1PNMTSLC6A2SLC6A4 | |
| Benzene SCHEMBL28092155 | 0.98 | TAAR1 (0.58) | TAAR1IDO1PNMTSLC6A2SLC6A4 | |
| SCHEMBL6681501 | 0.86 | TAAR1 (0.56) | TAAR1IDO1PNMTSLC6A2SLC6A4 | |
| SCHEMBL6679599 | 0.84 | TAAR1 (0.54) | TAAR1IDO1PNMTSLC6A2SLC6A4 | |
| SCHEMBL6740216 | 0.84 | TAAR1 (0.71) | TAAR1IDO1PNMTSLC6A2SLC6A4 | |
| SCHEMBL8071207 | 0.82 | TAAR1 (0.52) | TAAR1IDO1PNMTSLC6A2SLC6A4 | |
| SCHEMBL7562064 | 0.82 | TAAR1 (0.52) | TAAR1IDO1PNMTSLC6A2SLC6A4 | |
| SCHEMBL7563447 | 0.82 | TAAR1 (0.52) | TAAR1IDO1PNMTSLC6A2SLC6A4 | |
| SCHEMBL8070948 | 0.82 | TAAR1 (0.52) | TAAR1IDO1PNMTSLC6A2SLC6A4 | |
| SCHEMBL7562209 | 0.82 | TAAR1 (0.52) | TAAR1IDO1PNMTSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-12-25 | — | — | US | disclosed |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2025-10-23 | — | — | US | disclosed |
| EP-4568968-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Remynd N.V. (BE) | 2025-06-18 | — | — | EP | disclosed |
| CN-116283474-B | Method for catalyzing olefin migration by palladium | 常州大学 | 2025-05-27 | — | — | CN | disclosed |
| US-20240228502-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-11 | — | — | US | disclosed |
| WO-2024145659-A1 | HETEROCYCLE FUSED GAMMA-CARBOLINES ACTING ON THE SEROTONINE 5-HT2A RECEPTOR | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-11919921-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2024-03-05 | — | — | US | disclosed |
| WO-2024043334-A1 | NOVEL PIPERAZINE DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-6313312-B1 | OPIATE RECEPTOR BINDERS; ALLERGIC DERMATITIS, PRURITUS; IRRITABLE BOWEL SYNDROME, GASTROINTESTINAL AND SKIN DISORDERS; VETERINARY MEDICINE; ANTI-ITCHING | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| EP-1140828-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| US-6284934-B1 | SEPARATION OF HALOALKYLBENZENES, EXPOSURE TO BROMINE, REACTION TO FORM HYDROGEN BROMIDE AND HEATING | OCCIDENTAL CHEMICAL CORPORATION | 2001-09-04 | — | — | US | disclosed |
| WO-2001051437-A1 | REDUCING META CONTENT OF ISOMERIC MIXTURES OF HALO SUBSTITUTED ALKYLBENZENES | OCCIDENTAL CHEMICAL CORPORATION (US) | 2001-07-19 | — | — | WO | disclosed |
| US-6239129-B1 | CHARACTERISED BY AN INDOLE RING ON THE AROMATIC MOIETY BY A CYANO GROUP AND ON THE INDOLE NITROGEN BY AN AMINOALKYL CHAIN. GREAT AFFINITY FOR 5-HT2C RECEPTORS, USEFUL FOR DEPRESSION, PANIC ATTACKS, OBSESSIVE-COMPULSIVE DISORDERS, PHOBIAS, | ADIR ET COMPAGNIE (FR) | 2001-05-29 | — | — | US | disclosed |
| EP-1023898-A1 | Cyano-indoles as serotonine reuptake inhibitors and as 5-HT2c receptor ligands | ADIR ET COMPAGNIE (FR) | 2000-08-02 | — | — | EP | disclosed |
| WO-2000039089-A1 | 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
| US-5262420-A | Phenylalkylpyridines | IDEMITSU KOSAN CO., LTD. (JP) | 1993-11-16 | — | — | US | disclosed |
| EP-0383950-A1 | PYRIDINE DERIVATIVES AND INSECTICIDAL AND MITICIDAL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228502-A1 | 2-PHENYLAMINO PYRROLOPYRIMIDINES AS ACK1 INHIBITORS | ADCK1, DCK, TNKS2 | TAAR1 4717/4885IDO1 3888/4885PNMT 4186/4885 |
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | TAAR1 75/4885IDO1 738/4885PNMT 72/4885 |
| US-11919921-B2 | Galactoside inhibitor of galectins | LGALS3, LGALS1, LGALS2 | TAAR1 3201/4885IDO1 769/4885PNMT 1527/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | TAAR1 3573/4885IDO1 2074/4885PNMT 3973/4885 |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SNCA, CHRNA6, CHRNA5 | TAAR1 141/4885IDO1 1970/4885PNMT 1775/4885 |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | ABCB11, ABCC1, SLC11A2 | TAAR1 2444/4885IDO1 1848/4885PNMT 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.